A breast cancer pathology report can feel like a page of unfamiliar terms. Yet HER2 test results are among the findings that may shape discussions about your care in Malaysia.
Your specialist interprets HER2 alongside the cancer stage, tumour size and location, hormone receptor status, scans, lymph node findings, overall health, and specialist assessment. Together, these details help guide an individual treatment plan. Start by understanding what the report says, then bring your questions to the next appointment.
Key Takeaways
HER2 stands for human epidermal growth factor receptor 2. It is a protein linked to the ERBB2 gene. Some breast cancers make too much of this protein or carry extra copies of the gene through gene amplification.
- HER2-positive breast cancer is usually reported as IHC 3+, or IHC 2+ with amplification confirmed by an ISH or FISH test for standard targeted therapy decisions.
- IHC 0 and 1+ generally indicate HER2-negative breast cancer for standard treatment decisions.
- An IHC 2+ result is not a final positive result. It needs a further laboratory test.
- HER2-low breast cancer is treatment-related language used in some advanced breast cancer settings. Lower HER2 expression does not replace the standard positive or negative classification.
- If cancer returns or spreads, your doctor may consider repeat testing on a new tissue sample when one is available.
The National Cancer Institute’s biomarker overview explains why HER2 and hormone receptor findings are reported together.
What HER2 Testing Looks For
HER2 testing is a tissue-based tumor marker test using cancer cells taken during a breast biopsy or surgery. It evaluates the tumour itself, not your inherited risk of breast cancer.
Some cancers show HER2 protein overexpression. Others have extra copies of the ERBB2 gene, known as gene amplification. These findings describe tumour biology, including how HER2 may influence cell growth, but neither determines treatment on its own.
In Malaysia, breast cancer specialists commonly request HER2 testing as part of the pathology work-up for invasive breast cancer. The Malaysian Ministry of Health breast cancer guidance supports HER2 testing and links confirmed HER2 overexpression or amplification with trastuzumab-based treatment considerations. Such findings may be considered alongside the full pathology report and other clinical factors.
HER2 testing is also used in some stomach cancer cases and certain esophageal cancer contexts. However, those disease-specific criteria, including those for esophageal cancer, shouldn’t be used to interpret breast cancer results.
HER2 is only one piece of the report. Hormone receptor status, tumour grade, cancer stage, and lymph node status may all affect your diagnosis and treatment plan.
How to Read HER2 Test Results
Pathologists usually start with an immunohistochemistry test, often shortened to IHC, which evaluates HER2 protein on tumour-cell membranes. The score reflects protein staining pattern and intensity, not how serious the cancer is.
IHC scores from 0 to 3+
An IHC score of 0 means no staining, or only faint, incomplete staining in 10% or fewer invasive tumour cells. A score of 1+ means faint, incomplete staining in more than 10% of cells.
These findings are generally classified as HER2-negative breast cancer for standard HER2 treatment decisions, although the full laboratory interpretation also matters. An IHC score of 3+ means strong, complete membrane staining in more than 10% of invasive cancer cells. This supports a diagnosis of HER2-positive breast cancer.
A score of 2+ sits between these categories. It means the staining is weak or moderate, so additional testing is needed before doctors decide how to classify the result.
What ISH and FISH add
In situ hybridisation, or ISH, looks for extra copies of the ERBB2 gene inside cancer cells. Fluorescence in situ hybridization, known as FISH, is one type of ISH assay.
If an IHC 2+ sample shows gene amplification on ISH or FISH, the result may be interpreted as HER2-positive. Without amplification, it may be interpreted as HER2-negative under the standard classification, depending on the laboratory report and applicable testing framework.
The ASCO/CAP HER2 testing update continues to use this framework. Your report may use terms such as ISH, FISH, dual-probe, or single-probe, but the key point is how the laboratory interpreted HER2 status under the applicable framework.
What an IHC 2+ Result Means
An IHC 2+ result falls into the category of equivocal results. It requires clarification, but it doesn’t mean your cancer is definitely HER2-positive or that the test has failed. Protein staining alone cannot provide a final answer.
Why reflex testing matters
Your pathology laboratory may automatically carry out reflex ISH testing after an IHC 2+ result. In other settings, your doctor may request it. This second step can help clarify the HER2 classification and support the next treatment discussion.
The additional test can add time to the reporting process. Rather than relying on a fixed number of days, ask when your final result is expected and who will contact you.
Questions to bring to your appointment
Ask for a copy of the full pathology report. Then ask whether the sample came from a core needle biopsy of the breast or from surgery, whether ISH testing is pending, and whether the result changes your proposed care.
You can also ask whether the sample has enough invasive tumour for reliable testing. If results from a biopsy and later surgical specimen differ, your multidisciplinary team can explain which result guides care and why.
An IHC 2+ score is a request for clarification through gene testing, not a final HER2 diagnosis.
HER2-Low and HER2-Ultralow Results
HER2-low breast cancer generally refers to tumours reported as IHC 1+, or IHC 2+ with a negative ISH result. Under the conventional classification, these tumours remain HER2-negative. However, the precise IHC score may matter when discussing treatment options for metastatic breast cancer.
ASCO and CAP don’t define HER2-low or HER2-ultralow as new formal diagnostic categories. Malaysian pathology reports may still note lower HER2 expression because it can be relevant to certain treatments. Keep the precise IHC score and ISH result with your records.
HER2-ultralow is an emerging term, and its definition continues to change. It shouldn’t lead you to assume that a medicine is suitable or locally available. Your cancer specialist will consider it alongside hormone receptor status, previous treatment, cancer spread, organ function, and current evidence. HER2-low terminology in breast cancer shouldn’t automatically be applied to esophageal cancer, where reporting and treatment contexts may differ.
For selected unresectable or metastatic cases, the FDA’s treatment approval details describe the use of fam-trastuzumab deruxtecan-nxki in HR-positive HER2-low or HER2-ultralow disease. Approval, funding, and access differ between countries and hospitals, including in Malaysia.
How HER2 Status Can Affect Cancer Treatment
A HER2 result helps your oncology team shape a treatment plan around the cancer’s biology. HER2 is only one factor alongside stage, pathology, hormone receptors, medical history, overall health, and specialist assessment.
Treatment for HER2-positive breast cancer
For early-stage disease, treatment may include surgery, chemotherapy, radiotherapy, and targeted therapy. The order depends on the cancer stage and whether treatment before surgery is appropriate.
Trastuzumab is a well-established treatment. Depending on your situation, an oncologist may also discuss pertuzumab or other medicines, each with different roles and side-effect profiles.
Because some anti-HER2 medicines can affect heart function, your team may arrange heart assessments before or during treatment. This supports safe planning and doesn’t mean a heart problem is expected.
Treatment for lower HER2 expression
For HER2-low breast cancer, antibody-drug conjugates may be discussed for some metastatic breast cancer cases after earlier treatments. These medicines combine an antibody that targets cancer cells with an anti-cancer drug.
They aren’t standard treatment for everyone with IHC 1+ or IHC 2+/ISH-negative findings. Eligibility depends on the complete clinical picture, including hormone receptor status, previous therapy, symptoms, disease extent, potential risks, available evidence, and local access.
You can Explore Cancer Treatment Options for general education and question preparation before speaking with a specialist. Treatment recommendations must come from your qualified oncology team.
When Repeat Testing or a Review May Help
Cancer cells can vary between tumour areas, and their biomarker profile may change when cancer recurs or spreads. If metastatic tissue is safely available, doctors may test it again to guide treatment for advanced cancer.
A repeat test does not mean the first laboratory made an error. It may confirm the original result, clarify a borderline finding, or reveal a meaningful difference in a newer sample.
If you need a cancer second opinion, gather the pathology report, IHC and ISH results, biopsy details, imaging reports, treatment summaries, and slides or tissue-block information if requested. You can Explore Medical Report Review Support for help organising medical information for review coordination. This support does not diagnose cancer or replace a pathologist’s report.
A second opinion for cancer may confirm your current plan, explain it more clearly, recommend further assessment, or identify another medically appropriate approach. You can Explore Cancer Second Opinion Support for coordination assistance when seeking another qualified specialist’s perspective. This support coordinates information but does not replace that specialist’s assessment.
Different cancer hospitals may have different breast oncology teams, pathology services, drug access, waiting times, and treatment facilities. If you are considering care outside Malaysia, Explore Overseas Hospital Options for medical travel and hospital-enquiry coordination. Another hospital or country does not automatically provide a better outcome.
FAQ About HER2 Results
Does HER2-positive mean the cancer is more serious?
HER2-positive breast cancer can influence tumour behaviour and treatment discussions. However, HER2 status alone doesn’t determine a person’s recurrence risk or outcome. Stage, response to treatment, hormone receptor findings, overall health, and the complete pathology report also matter.
Can HER2 results change after cancer comes back?
Results can differ between the original tumour and a metastatic breast cancer sample. Therefore, your oncologist may suggest a repeat biopsy only when tissue is safely available and the result could affect a treatment decision.
Can a breast biopsy cause cancer to spread?
A core needle biopsy is a standard way to obtain tissue for pathology testing. Your treating team will explain the procedure and review individual risks beforehand. Tell them about blood-thinning medicines, allergies, or health conditions that could affect the procedure.
A Clear Next Step After Your Results
Your HER2 result gives your treatment team important biological information, but it’s only one part of your care. Keep a copy of your complete written results, ask whether any testing is pending, and discuss how the result fits into your treatment plan.
Medical disclaimer: This content is for general educational information only. It may not apply to every patient and is not medical advice, a diagnosis, or a treatment recommendation. Consult your own doctor, oncologist, or qualified healthcare professional before making medical decisions.
